Abstract
The pharmacology characteristics of dihydropyridine calcium channel blockers (CCB) make them an attractive antihypertensive medication for use in the perioperative setting of coronary artery bypass graft (CABG) surgery. They lack the negative inotropic, negative chronotropic, and negative bathmotropic effects of phenylalkylamine and benzothiazepine CCB that limit the use in patients with heart failure or patients with bradyarrythmias. With the aging population and significant rise in the prevalence of heart failure, the use of dihydropyridine CCB as antihypertensive medication after CABG surgery has become more common. Furthermore, intravenous dihydropyridine CCB are being used in the perioperative setting as vasodilatory agents after radial artery harvesting for total arterial coronary revascularization. We review the pharmacological effects of intravenous dihydropyridine CCB, analyze the literature, and comment on the consequences in modern clinical practice.
Keywords: Coronary artery bypass graft, complications, hypertension, calcium channel blockers, afterload reduction
Current Vascular Pharmacology
Title: The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Volume: 6 Issue: 3
Author(s): Ali Khoynezhad, Paul P. Dobesh, Zachary Stacy and Ziba Jalali
Affiliation:
Keywords: Coronary artery bypass graft, complications, hypertension, calcium channel blockers, afterload reduction
Abstract: The pharmacology characteristics of dihydropyridine calcium channel blockers (CCB) make them an attractive antihypertensive medication for use in the perioperative setting of coronary artery bypass graft (CABG) surgery. They lack the negative inotropic, negative chronotropic, and negative bathmotropic effects of phenylalkylamine and benzothiazepine CCB that limit the use in patients with heart failure or patients with bradyarrythmias. With the aging population and significant rise in the prevalence of heart failure, the use of dihydropyridine CCB as antihypertensive medication after CABG surgery has become more common. Furthermore, intravenous dihydropyridine CCB are being used in the perioperative setting as vasodilatory agents after radial artery harvesting for total arterial coronary revascularization. We review the pharmacological effects of intravenous dihydropyridine CCB, analyze the literature, and comment on the consequences in modern clinical practice.
Export Options
About this article
Cite this article as:
Khoynezhad Ali, Dobesh P. Paul, Stacy Zachary and Jalali Ziba, The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery, Current Vascular Pharmacology 2008; 6 (3) . https://dx.doi.org/10.2174/157016108784911993
DOI https://dx.doi.org/10.2174/157016108784911993 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure
Current Pharmaceutical Design Targeting the Mevalonate Pathway for Improved Anticancer Therapy
Current Cancer Drug Targets COX-Inhibiting Nitric Oxide Donors (CINODs): Potential Benefits on Cardiovascular and Renal Function
Cardiovascular & Hematological Agents in Medicinal Chemistry The Progress Towards the Development of DHQO Derivatives and Related Analogues with Inotropic Effects
Mini-Reviews in Medicinal Chemistry Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) Agonists on Glycemic Control, Lipid Profile and Cardiovascular Risk
Current Molecular Pharmacology Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Left Ventricular Hypertrophy and Angiotensin II Receptor Blocking Agents
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Pluripotent Stem Cells for Gene Therapy of Degenerative Muscle Diseases
Current Gene Therapy Development of a Radiolabeled Amlodipine Analog for L-type Calcium Channel Imaging
Current Radiopharmaceuticals Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Cytokine Gene Polymorphism in Heart Transplantation: A Review
Current Genomics Medical Management of the Diabetic Patient with Coronary Artery Disease
Current Pharmaceutical Design Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Endothelial Cell Aging and Apoptosis in Prevention and Disease: E-Selectin Expression and Modulation As A Model
Current Pharmaceutical Design Molecular Targeting of Acid Ceramidase: Implications to Cancer Therapy
Current Drug Targets The Synthesis of Nano-Doxorubicin and its Anticancer Effect
Anti-Cancer Agents in Medicinal Chemistry Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium
Current Signal Transduction Therapy Lower Financial Status and Adherence to Medication Determines 10-Year (2004-2014) All-Cause Mortality and Risk for Acute Coronary Syndrome Incidence Among Cardiac Patients: the GREECS Study
Current Vascular Pharmacology